Disposition and metabolism of 2-(2''(1'',3''-dioxolan-2-YL)-2-methyl-4- (2'-oxopyrrolidin-1-YL)-6-nitro-2H-1-benzopyran (SKP-450) in rats

Drug Metabolism and Disposition

Volumn 27, Issue 4, 1999, Pages 510-516

  Baek, Minsun ^a   Chung, Hak Soon ^a   Kim, Yunje ^a   Kim, Dong Hyun ^a  

^a Korea Institute of Science and Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1,3 DIOXOLAN 2 YL) 2 METHYL 6 NITRO 4 (2 OXO 1 PYRROLIDINYL) 2H 1 BENZOPYRAN; ANTIHYPERTENSIVE AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOACTIVITY; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BIOTRANSFORMATION; CARBON RADIOISOTOPES; INJECTIONS, INTRAVENOUS; MALE; POTASSIUM CHANNELS; PROTEIN BINDING; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; VASODILATOR AGENTS;

EID: 0345490933     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Damiano BP, Giardino EC, Haertlein BJ, Stump GL, Mitchell JA and Falotico R (1994) Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs. J Cardiovasc Pharmacol 23:300-310.
2. Edsbacker S, Jonsson S, Lindburg C, Ryrfeldt A and Thalen A (1983) Metabolic pathways of the topical glucocorticoid budesonide in man. Drug Metab Dispos 11:590-596.
3. Grosta G, Franzone JS and Biglino G (1986) Metabolism of doxophyllinc by rat liver microsomes. Drug Metab Dispos 14:267-270.
4. Keiji K, Yumiko A, Takahito K, Shuji F, Shouhei H, Zen-ichi T, Mitsuru S and Toshifumi W (1994) Antihypertensive and cardiovascular effects of a new potassium channel opener, TCV-295, in rats and dogs. J Cardiovasc Pharmacol 24:929-936.
5. + channel. J Pharmacol Exp Ther 275:807-812.
6. Lawson K. Barras M, Zazzi-Sudriez E, Martin DJ, Armstrong JM and Hicks PE (1992) Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers. Br J Pharmacol 107:58-65.
7. Lee BH, Yoo SE and Shin HS (1998a) Hemodynamic profile of SKP-450. a new potassium-channel activator. J Cardiovasc Pharmacol 31:85-94.
8. Lee H, Yeom HY. Kim YG, Yoon CN, Jin CB, Choi JS, Kim BR and Kim DH (1998b) Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem Pharmacol 55:1369-1375.
9. Lee JH, Kwon KI and Shin HS (1997) The pharmacological effects of KR-30450, a potassium channel opener on coronary artery occlusion/reperfusion-induced myocardial infarction in the rat. Yakhak Hoeji 41:117-125.
10. Lin JH, Sugiyama Y, Awazu S and Hanano M (1982) Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharmacol 10:649-661.
11. Maurer HH and Fritz CF (1990) Metabolism of pholcodine in man. Arzneim-Forsch/Drug Res 40:564-566.
12. + channel opener with less tachycardia: Antihypertensive effects in hypertensive rats and dogs in conscious state. J Pharmacol Exp Ther 261(Suppl 2):730-736.
13. + ATP-channel activation causes marked vasodilation in the hypertensive neonatal pig lung. Am J Physiol 263:1532-1536.
14. Robertson DW and Steinberg M (1990) Potassium channel modulators: Scientific applications and therapeutic promise. J Med Chem 33:1529-1541.
15. Schatz F, Haberl H, Battig F, Jobstmann D, Schulz G, Nefzger M, Czok R and Nikiforov A (1986) Major routes of naftifine biotransformation in laboratory animals and man. Arzneim-Forsch/Drug Res 36:248-255.
16. Shin HS, Seo HW, Oh JH and Lee BH (1998) Antihypertensive effects of SKP-450 and its major metabolites in rats. Arzneim-Forsch Drug Res 48(Suppl II):969-978.